Bank Of America Corp Alpine Immune Sciences, Inc. Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.75 - $41.6 $1.96 Million - $4.6 Million	110,648 Added 120.58%	202,414 $8.02 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $630,687 - $1.49 Million	73,851 Added 412.23%	91,766 $1.75 Million
Q2 2023 Aug 14, 2023	SELL	$6.84 - $11.91 $38,201 - $66,517	-5,585 Reduced 23.77%	17,915 $184,000
Q1 2023 May 12, 2023	SELL	$7.0 - $8.75 $1,162 - $1,452	-166 Reduced 0.7%	23,500 $181,000
Q4 2022 Feb 10, 2023	BUY	$5.45 - $7.35 $93,058 - $125,501	17,075 Added 259.07%	23,666 $173,000
Q3 2022 Nov 14, 2022	SELL	$6.89 - $9.39 $22,626 - $30,836	-3,284 Reduced 33.26%	6,591 $47,000
Q2 2022 Aug 12, 2022	SELL	$6.71 - $9.52 $37,354 - $52,997	-5,567 Reduced 36.05%	9,875 $84,000
Q1 2022 May 16, 2022	BUY	$6.41 - $13.89 $67,292 - $145,817	10,498 Added 212.34%	15,442 $138,000
Q4 2021 Feb 08, 2022	BUY	$10.41 - $13.95 $16,374 - $21,943	1,573 Added 46.66%	4,944 $69,000
Q3 2021 Nov 15, 2021	BUY	$8.19 - $11.31 $9,377 - $12,949	1,145 Added 51.44%	3,371 $36,000
Q2 2021 Sep 13, 2021	BUY	$8.81 - $15.03 $19,611 - $33,456	2,226 New	2,226 $20,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.